Antwerp, Belgium, November 17, 2025. Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA Phase 2a clinical trial for ontunisertib (AGMB-129), an investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).